Fairvalue-Calculator Fairvalue-Calculator
EN DE

NEXGEL, Inc (NXGL) Fair Value & Analysis

Healthcare · US · Market cap $5.2M

Price$0.5401
Fair Value$0.3200
Upside-40.8%
Quality89/100
Evidence: Low Range $0.2400 – $0.4800

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

NEXGEL, Inc (NXGL) currently trades at $0.5401, while our model-based Fair Value estimate is $0.3200 — implying the stock looks roughly 40.8% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -61% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -43% Medline Inc (MDLN) -5% Becton, Dickinson and Company (BDX) -16% Alcon Inc (ALC) -44%

Frequently asked questions

Is NEXGEL, Inc (NXGL) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.3200 versus a price of $0.5401 — about −41% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NXGL?
Our 21-model fair value for NEXGEL, Inc is $0.3200 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.5401.
What is the quality score of NXGL?
NEXGEL, Inc has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.